(Beijing, 28 September 2020) – China Renaissance Holdings Limited ("China Renaissance") ("China Renaissance" or the "Company", stock code: 1911.HK) today announced that it served as the exclusive financial advisor for XtalPi, an algorithm-driven artificial intelligence pharmaceutical technology company, in its Series C financing. XtalPi raised a record breaking US$319 million and marked the largest single funding round in the global pharmaceutical technology industry. 

The financing round was led by the SoftBank Vision Fund, PICC Capital and Morningside Venture Capital. Other Series C investors included CICC Capital, CMB International, Mirae Asset Global Investment, CITIC Securities Capital, CITIC Capital, Oceanpine Capital, Shunwei Capital, Foursquare Capital, IMO Ventures and Parkway Life Real Estate Investment Trust. Existing shareholders, including Tencent, Sequoia Capital, China Life Private Equity Investment and SIG Asia Investment also participated in the financing round.     

Founded in 2014 by a group of quantum physicists at Massachusetts Institute of Technology ("MIT"), XtalPi has been reinventing the industry's approach to drug research and development ("R&D") with its Intelligent Digital Drug Discovery and Development ("ID4") platform. ID4 leverages quantum physics, quantum chemistry, artificial intelligence and high-performance cloud computing algorithms. Since its inception, XtalPi has provided intelligent drug R&D solutions for over 40 industry-leading pharmaceutical companies across the Unites States, Europe, China and Japan.    

XtalPi will use the new funding to further reinforce its AI-empowered intelligent digital drug R&D infrastructure to enhance the efficiency of drug development, serving global pharmaceutical companies, biotechnology companies and business partners globally.